Azathioprine and mesalazine-induced effects on the mucosal flora in patients with IBD colitis

Inflammatory Bowel Diseases

Volumn 13, Issue 1, 2007, Pages 51-56

  Swidsinski, Alexander ^a   Loening Baucke, Vera ^a   Bengmark, Stig ^b   Lochs, Herbert ^a   Dörffel, Yvonne ^c  

^a HUMBOLDT UNIVERSITY   (Germany)

^b ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Azathioprine; FISH; IBD; Mesolazine; Mucosal flora

Indexed keywords

AZATHIOPRINE; MESALAZINE; PREDNISOLONE; RNA 16S;

ADULT; ARTICLE; BACTERIUM ADHERENCE; COLITIS; COLON BIOPSY; COLONOSCOPY; CONTROLLED STUDY; ENTERITIS; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN TISSUE; INNATE IMMUNITY; INTESTINE FLORA; LEUKOCYTE MIGRATION; MAJOR CLINICAL STUDY; MALE; MUCUS; NONHUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; RNA PROBE; ULCERATIVE COLITIS;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; AZATHIOPRINE; BACTERIA; BACTERIAL ADHESION; COLITIS; COLITIS, ULCERATIVE; COLON; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFLAMMATORY BOWEL DISEASES; INTESTINAL MUCOSA; MALE; MESALAMINE; MIDDLE AGED;

EID: 33846133717     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20003     Document Type: Article

References (23)

1. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
2. Jiang XL, Cui HF. An analysis of 10218 ulcerative colitis cases in China. World J Gastroenterol. 2002;8:158-161.
3. Sands BE. Immunosuppressive drugs in ulcerative colitis: twisting facts to suit theories? Gut. 2006;55:437-441.
4. Fraser GA, Orchard TR, Jewell DP. The efficacy of azathioprine for the treatment of inflammatory bowel disease: a 30 year review. Gut. 2002;50;485-489.
5. Ardizzone S, Maconi G, Russo A, Imbesi V, Colombo E, Bianchi Porro G. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut. 2006;55:47-53.
6. Swidsinski A, Ladhoff A, Pernthaler A, et al. Mucosal flora in inflammatory bowel disease. Gastroenterology. 2002;122:44-54.
7. Swidsinski, A, Weber J, Loening-Baucke V, Hale LP, Lochs H. Spatial organization and composition of the mucosal flora in patients with inflammatory bowel disease. J Clin Microbiol. 2005;43:3380-3389.
8. Sands BE. From symptom to diagnosis: clinical distinctions among various forms of intestinal inflammation. Gastroenterology. 2004;126:1518-1532.
9. Snaidr J, Amann R, Huber L, Ludwig W, Schleifer KH. Phylogenetic analysis and in situ identification of bacteria in activated sludge. Appl Environ Microbiol. 1997;63:2884-2896.
10. Manz W, Amann R, Ludwig W, Vancanneyt M, Schleifer KH. Application of a suite of 16S rRNA-specific oligonucleotide probes designed to investigate bacteria of the phylum Cytophaga-Flavobacter-Bacteroides in the natural environment. Microbiology. 1996;142:1097-1106.
11. Franks AH, Harmsen HJ, Raangs GC, Jansen GJ, Schut F, Welling GW. Variations of bacterial populations in human feces measured by fluorescent in situ hybridization with group-specific 16S rRNA-targeted oligonucleotide probes. Appl Environ Microbiol. 1998;64:3336-3345.
12. Suau A, Rochet V, Sghir A, et al. Fusobacterium prausnitzii and related species represent a dominant group within the human fecal flora. Syst Appl Microbiol. 2001;24:139-145.
13. Bohnert J, Hübner B, Botzenhart K. Rapid identification of Enterobacteriaceae using a novel 23S rRNA-targeted oligonucleotide probe. Int J Hyg Environ Health. 2002;203:77-82.
14. Mantzaris GJ, Sfakianakis M, Archavlis E, et al. A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol. 2004;99:1122-1128.
15. Campbell S, Ghosh S. Effective maintenance of inflammatory bowel disease remission by azathioprine does not require concurrent 5-aminosalicylate therapy. Eur J Gastroenterol Hepatol. 2001;13:1297-1301.
16. Amann RI, Ludwig W, Schleifer KH. Phylogenetic identification and in situ detection of individual microbial cells without cultivation. Microbial Rev. 1995;59:143-169.
17. Svartz N. Salazopyrin, a new sulfanilamide preparation. A: therapeutic results in rheumatic polyathritis. B: therapeutic results in ulcerative colitis. C: toxic manifestations in treatment with sulfanilamide preparations. Acta Med Scand. 1942;110:557-590.
18. Truelove SC, Witts LJ. Cortisone in ulcerative colitis therapeutic trial. Br Med J. 1955;4947:1041-1048.
19. Bean RHP. The treatment of chronic ulcerative colitis with 6-mercaptopurine. Med J Aust. 1962;2:592-593.
20. Brooke BN, Hoffmann DC, Swarbrick ET. Azathioprine for Crohn's disease. Lancet. 1969;2:612-614.
21. Azad Khan AK, Piris J, Truelove SC. An experiment to determine the active therapeutic moiety of sulphasalazine. Lancet. 1977;2:892-895.
22. Bergman R. Parkes M. Systematic review: the use of mesalazine in inflammatory bowel disease. Aliment Pharmacol Ther. 2006;23:841-855.
23. Caprilli R, Gassull MA, Escher JC, et al. and European Crohn's and Colitis Organisation. European evidence based consensus on the diagnosis and management of Crohn's disease: special situations. Gut. 2006;55(Suppl 1):i36-i58.